

## Technology Advisory Committee C Interests Register

Topic [ID6333]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Satish Venkateshan	TAC C Committee Member	Direct- financial	Regeneron is developing livoseltamab a BCMAxCD3 bispecific in multiple myeloma. Satish Venkateshan works for Regeneron, pharmaceuticals/biotech company. Satish Venkateshan also owns shares in the company and has stock options.	18/05/2024	It was agreed that Satish Venkateshan's declaration would prevent him from participating in discussions on this appraisal.
Michael Chambers	TAC C Committee Member	Direct- financial	Michael Chambers has participated in an advisory panel for Pfizer in an unrelated disease area (prostate cancer) and has provided consulting advice to Sanofi in an unrelated disease area (COPD). Concluding Sept 2022. Michael Chambers supported Takeda's contributions to Innovative Medicine Initiative (IMI) projects, but this did not involve consideration of Takeda products.	17/05/2024	It was agreed that Michael Chambers' declaration would not prevent him from participating in discussions on this appraisal.



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Myers Squibb), Janssen, Pfizer, Sanofi and Takeda.		
Rakesh Popat	Clinical expert	Direct- financial	<p>Rakesh Popat is the PI for clinical trials that are sponsored by Johnson &amp; Johnson Innovative Medicine.</p> <p>Rakesh Popat has received fees from Johnson &amp; Johnson Innovative Medicine for speaking and consultancy advice.</p> <p>Rakesh Popat has received speaker and consultancy fees from comparator companies BMS, Pfizer and Sanofi, all unrelated to this product.</p> <p>Rakesh Popat has received research funding from Pfizer.</p> <p>Rakesh Popat is on the executive board of the UK Myeloma Society</p>	12/12/2023	It was agreed that Rakesh Popat's declaration would not prevent him from providing expert advice to the committee.
Caroline Donoghue	Patient expert	Non-direct financial interest	Caroline Donoghue's nominating organisation, Myeloma UK, has received funding from Johnson & Johnson Innovative Medicine in the	12/12/2023	It was agreed that Caroline Donoghue's declaration would not prevent her from

<b>Name</b>	<b>Role with NICE</b>	<b>Type of interest</b>	<b>Description of interest</b>	<b>Interest declared</b>	<b>Comments</b>
			past 12 months. Myeloma UK has previously received funding from comparator companies Celgene, BMS, Pfizer, Sanofi and Takeda.		providing expert advice to the committee.

DRAFT